Profound Medical Cuts Q2 Net Loss 39% as $3.1M Revenue Slips to Q3
Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) cut its second-quarter 2026 net loss 39% to about $9.5 million, or $0.26 per share, from $15.7 million, or $0.52 per share, a year earlier. Operating expenses fell 16% to about $13.0 million, and the company reiterated its full-year revenue guidance of about $25.0 million.
Shipment delay pushes $3.1 million of TULSA revenue into July
Q2 revenue was about $2.5 million, up 12% year over year. Recurring non-capital revenue from single-use devices and extended-warranty services contributed $1.6 million, and capital equipment sales added $871,000.
About $3.1 million of TULSA product shipments expected in the final week of June went out in July and will be recognized in Q3. Excluding the delay, Q2 revenue would have been about $5.6 million, or 153% growth. The company attributes the slip to a logistics issue, not weaker demand, and says the issue is resolved.